Mast cell activation pathway

The mast cell activation pathway is a complex signaling cascade primarily initiated by the cross-linking of high-affinity IgE receptors (FcεRI) on the surface of mast cells by allergens [1]. This activation triggers a series of intracellular events involving tyrosine kinases such as Spleen tyrosine kinase (SYK) and Bruton's tyrosine kinase (BTK) [2]. These signaling events lead to the rapid release of preformed mediators like histamine, heparin, and proteases through a process known as degranulation [2]. Additionally, the pathway stimulates the de novo synthesis of lipid mediators, including leukotrienes and prostaglandins, and the secretion of various pro-inflammatory cytokines [3]. This pathway plays a central role in Type I hypersensitivity reactions, contributing to conditions such as allergic rhinitis, asthma, and life-threatening anaphylaxis [4]. Therapeutic strategies targeting this pathway include monoclonal antibodies that sequester IgE, mast cell stabilizers that prevent mediator release, and small-molecule inhibitors of key signaling enzymes [5]. Dysregulation or over-activation of this pathway is also a hallmark of mast cell activation syndrome (MCAS) and systemic mastocytosis [6]. Monitoring of this pathway in clinical settings often involves measuring biomarkers such as serum tryptase or urinary histamine metabolites [1]. Overall, the mast cell activation pathway represents a critical node in the immune system's response to allergens and a major focus for anti-inflammatory drug development.

Other names

Mast cell degranulation pathwayFcεRI signaling pathwayIgE-mediated mast cell activation

Inhibition of IgE binding to FcεRI, stabilization of mast cell membranes to prevent mediator release, or inhibition of intracellular signaling kinases such as SYK, BTK, and KIT.